Cold Agglutinin Disease (CAD): A Patient Guide
At a Glance
Cold agglutinin disease is an autoimmune blood disorder in which cold-sensitive antibodies damage red blood cells. Management includes avoiding cold, using warmed testing and transfusions when needed, and medicines that target the abnormal cells or immune destruction.
Cold Agglutinin Disease (CAD) is a rare type of autoimmune hemolytic anemia where your immune system mistakenly identifies your red blood cells as foreign and destroys them. The hallmark of this condition is its sensitivity to temperature: the antibodies responsible for the destruction, called cold agglutinins, typically activate and attach to your red blood cells when they are exposed to cooler temperatures [1][2]. Once these antibodies attach, they trigger a series of immune proteins called the complement system, which tags the cells for removal by your liver or causes them to break apart directly in your bloodstream [2][3].
Your medical team will distinguish between two forms of this condition: Primary CAD and Secondary Cold Agglutinin Syndrome (CAS). Primary CAD is considered its own standalone disease, caused by a slow-growing group of cells (a B-cell clone) in your bone marrow that produces the cold-sensitive antibodies [4][1]. In contrast, Secondary CAS is a side effect of another health issue, such as a recent infection like pneumonia or mono, or an underlying condition like lymphoma [3]. Identifying which form you have is the first step in creating an effective care plan, as the cause dictates how the condition is managed.
Living with CAD requires a new level of vigilance regarding temperature and medical care. Because your blood can “clump” and break down when chilled, you may experience profound fatigue from anemia or circulatory issues like fingers and toes turning blue in the cold [5][6]. You may also face a higher risk of blood clots, making it vital to stay active and monitor for unusual swelling or pain [7]. One of the most important things you can do as a patient is to ensure your specific medical samples (like cold-agglutinin titers) and any necessary blood transfusions are handled with specialized warming protocols, as standard lab procedures can sometimes lead to inaccurate results or adverse reactions, though you should never delay life-saving care [8][9].
While a rare diagnosis can feel isolating, CAD is a condition that can often be managed effectively. Many patients find success through a combination of lifestyle changes—such as sensible cold avoidance—and modern medical therapies that either target the B-cell clone or block the complement system’s ability to destroy red blood cells [5][10]. By understanding the biology of your condition and advocating for the specialized care it requires, you can take control of your health and maintain a high quality of life.
In this guide
5 chapters
Understanding Your Diagnosis: CAD vs. CAS
Learn how primary cold agglutinin disease (CAD) differs from secondary cold agglutinin syndrome (CAS), including causes, testing, symptoms, and monitoring.
Recognizing Symptoms and Warning Signs
Learn to recognize cold agglutinin disease symptoms, hemolytic crisis warning signs, blood clot symptoms, and when jaundice or dark urine needs urgent care.
Decoding Your Labs and Diagnosis
Learn how Cold Agglutinin Disease labs confirm diagnosis, including DAT, cold agglutinin titer, thermal amplitude, hemolysis markers, and bone marrow tests.
Standard Treatment Strategies for CAD
Learn when cold agglutinin disease needs treatment and compare watchful waiting, rituximab, bendamustine-rituximab, and sutimlimab, including key safety steps.
Daily Management and Long-Term Wellness
Learn how to manage cold agglutinin disease with cold avoidance, warmed lab samples and transfusions, lab monitoring, clot prevention, and patient support.
Common questions in this guide
What is the difference between primary CAD and secondary cold agglutinin syndrome?
Why do cold temperatures make CAD symptoms worse?
Why do CAD blood tests need special handling?
What should the hospital blood bank know if I need a transfusion with CAD?
When is medication considered for cold agglutinin disease?
Does CAD increase the risk of blood clots?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Cold agglutinin disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Have we definitively determined if I have primary Cold Agglutinin Disease (CAD) or secondary Cold Agglutinin Syndrome (CAS)?
- 2.Do my lab records confirm that my CAD-specific blood samples were kept warm to ensure accurate results?
- 3.How will we decide when my anemia or symptoms are severe enough to move from lifestyle adjustments to drug treatment?
- 4.What is the plan for communicating with the hospital's blood bank if I ever need an emergency transfusion?
- 5.What are the specific markers and symptoms we will use to monitor my disease activity over the long term?
References
References (10)
- 1
Diagnosis and management of cold agglutinin disease.
Berentsen S
Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.
PMID: 41348049 - 2
Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape.
Choi DH
Blood research 2026; (61(1)).
PMID: 42696222 - 3
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.
Berentsen S
Frontiers in immunology 2020; (11()):590 doi:10.3389/fimmu.2020.00590.
PMID: 32318071 - 4
Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.
Berentsen S
Current oncology reports 2024; (26(9)):1085-1096 doi:10.1007/s11912-024-01569-8.
PMID: 38874820 - 5
[Cold agglutinin disease (CAD)].
Röth A, Borchert K, Dorn C, et al.
Innere Medizin (Heidelberg, Germany) 2025; (66(9)):986-996 doi:10.1007/s00108-025-01926-0.
PMID: 40691722 - 6
How I manage patients with cold agglutinin disease.
Berentsen S
British journal of haematology 2018; (181(3)):320-330 doi:10.1111/bjh.15109.
PMID: 29363757 - 7
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.
Broome CM, Cunningham JM, Mullins M, et al.
Research and practice in thrombosis and haemostasis 2020; (4(4)):628-635 doi:10.1002/rth2.12333.
PMID: 32548562 - 8
[Cold agglutinin disease: pathology, diagnosis, and treatment].
Wada H
[Rinsho ketsueki] The Japanese journal of clinical hematology 2024; (65(6)):521-528 doi:10.11406/rinketsu.65.521.
PMID: 38960651 - 9
IgA plasma cell myeloma presenting as cold agglutinin-induced haemolytic transfusion reaction.
Mehdipour Dalivand M, Woddor N, Makuria A, et al.
BMJ case reports 2024; (17(2)) doi:10.1136/bcr-2022-251638.
PMID: 38423573 - 10
Sutimlimab: First Approval.
Dhillon S
Drugs 2022; (82(7)):817-823 doi:10.1007/s40265-022-01711-5.
PMID: 35412113
This page is for informational purposes about cold agglutinin disease and does not constitute medical advice. Your treating clinician and blood bank should guide decisions about testing, transfusions, and treatment for your situation.